SEATTLE– Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Bogotá, Colombia-based Gencell Pharma to extend Parse’s reach in Colombia specifically and also across South America.
“Demand for Parse’s Evercode single cell sequencing solutions continues to grow in South America as the academic, biotech, and pharma communities discover their scalability and simplicity,” noted Parse Biosciences CEO and co-founder Alex Rosenberg, Ph.D. “Through this partnership with Gencell, we are empowering them to easily adopt the leading single cell sequencing technology.”
The company’s agreement with Gencell Pharma will give South American researchers full access to Parse’s single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode BCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, CRISPR Detect, and the Parse Biosciences data analysis solution, Trailmaker. The agreement is a continuation of Parse’s ongoing introduction of its products in key international markets, which are also currently available in North America, Europe, Australia, South Korea, Singapore, India, Israel, and New Zealand.
Noted Gencell Pharma CEO Fabio Andres Zapata Gomez, “This partnership with Parse will bring single cell sequencing to a wide range of researchers in South America, all of whom will greatly benefit from its Evercode technology. We’re excited to see what breakthroughs the scientific community in South America is able to achieve with these newly available tools.”
